News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Imugene Limited (IMU.AX) to Acquire Biolife Science Qld Limited


10/23/2013 7:00:10 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Imugene to Acquire Biolife Science Qld Limited

MELBOURNE--(BUSINESS WIRE)-- Australian drug development and pharmaceutical company Imugene (IMU.AX) is pleased to advise that, consistent with its strategy to diversify through acquisition, it has today executed a Sale and Purchase Agreement to acquire 100% of Biolife Science Qld Limited (Biolife), a company incorporated in Australia.

Biolife has the rights to a novel cancer immunotherapy platform that has been developed by scientists at the University Medical School in Austria. The scientists have developed a peptide-based immunotherapy that induces a polyclonal antibody response against HER-2/neu associated tumours, including breast cancer and gastric cancer (“HER-Vaxx”).

HER-2/neu is a known and validated receptor that is over-expressed on various cancerous tumours, including gastric, breast, ovarian and pancreatic cancers. Having already successfully completed a Phase I human study in breast cancer, a Phase II study in gastric cancer is planned to potentially commence in calendar 2015, subject to FDA approval.

Forrest Capital coordinated the acquisition and will be lead manager for the capital raise.

Key information on the Biolife technology, intellectual property, market potential and previous studies are included in a presentation and Q&A placed on the ASX website at: http://www.asx.com.au/asxpdf/20131023/pdf/42k77b8ttqdhsx.pdf

Imugene will, subject to Shareholder approval:

Issue 300 million shares to purchase 100% of Biolife Science Qld Ltd.

Raise an additional A$2.5 million via the placement of 250 million shares at $0.01. The placement will be managed by Forrest Capital, 85 million shares issued within current capacity with the balance subject to shareholder approval.

Dr Axel Hoos current vice president, Oncology R&D at GlaxoSmithKline is expected to join the board as Non-Executive Director.

Contact:

Imugene

Dr Nick Ede, +61 400 642 254

Executive Director

nede[at]imugene.com

or

Media:

College Hill

Dr. Douglas Pretsell, +61 3 9657 0706

douglas.pretsell[at]collegehill.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES